Longboard Pharmaceuticals (LBPH)
(Delayed Data from NSDQ)
$34.88 USD
0.00 (0.00%)
Updated Aug 13, 2024 04:00 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Brokerage Reports
Longboard Pharmaceuticals, Inc. [LBPH]
Reports for Purchase
Showing records 41 - 60 ( 65 total )
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Phase 1b/2a Data on Lead Epilepsy Compound LP352 on Track for 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Notes From The (Virtual) Road... Check-In With Management Ahead of PACIFIC Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
California Dreamin'' As PACIFIC Data On Track For 4Q23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Lead Epilepsy Compound LP352 on Track for Phase 2 Data in 2H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Data Demonstrates Differentiated CNS PK/PD Profile of LP352, Lead Epilepsy Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Lead Epilepsy Program LP352 With Broad Potential on Track for Clinical Data Readouts in 4Q22 and 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Liking the Setup As We Get Closer to PACIFIC - 3Q22 Highlights
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; LP352 Remains on Track to Complete Phase 1b/2a Trial by 2H23; LP659 IND Filling Expected 4Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Rolling Right Along - LBPH''s PACIFIC Continues To Cruise
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Robust Phase 3 Etrasimod Data Provides Positive Read-Through to Science Underpinning Longboard''s Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Underappreciated LP352 Epilepsy Program Progressing; S1P Modulator LP659 IND Filing Expected 4Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P